Blood biomarkers role in acute ischemic stroke patients: higher is worse or better?
- Equal contributors
1 Clinical Epidemiology & Biostatistics Unit, IRCCS INM Neuromed, Pozzilli (IS), Italy
2 Stroke Unit, IRCCS INM Neuromed, Pozzilli (IS), Italy
3 Vascular Physiopathology Unit, IRCCS INM Neuromed, Pozzilli (IS), Italy
4 Diagnostical & Therapeutical NeuroRadiology Unit, IRCCS INM Neuromed, Pozzilli (IS), Italy
5 Department of Neuroscience, University of Naples Federico II, Naples (NA), Italy
6 Department of Clinical Medicine, Cardiovascular and Immunological Sciences, University of Naples Federico II, Naples (NA), Italy
7 NeuroRehabilitation Unit, IRCCS INM Neuromed, Pozzilli (IS), Italy
8 AngioCardioNeurology Unit, IRCCS INM Neuromed, Pozzilli (IS), Italy
9 Cardiovascular Research Unit, IRCCS Multimedica, Milano, Italy
10 Department of Medicine and Surgery, University of Salerno, Salerno, Italy
Immunity & Ageing 2012, 9:22 doi:10.1186/1742-4933-9-22Published: 31 October 2012
Thrombolytic therapy (TT) for acute ischemic stroke (AIS) can provoke bleeding’s complication depending on the ischemic lesion (IL) dimension. Inflammation involved in the setting of acute ischaemic stroke, is associated with infarct size. We aimed to study the independent correlation and association between clinical panel of routinely identified biomarkers, including inflammatory parameters, and cerebral IL dimension and site.
We evaluated eleven biomarkers in 105 unrelated patients during their hospitalization after acute stroke event. Our data indicate a significant association of: a) confluent IL size with 4th quartile of Erythrocyte Sedimentation Rate (ESR) (OR = 5.250; 95% CI, 1.002 to 27.514) and an independent correlation with sex; b) confluent IL size with 3rd quartile of fibrinogen (OR = 5.5; 95% CI, 1.027 to 29.451); c) confluent IL size with 3rd quartile of platelets (OR= 0.059; 95% CI, 0.003 to 1.175) and independent correlation with sex; d) smaller IL size (OR = 5.25; 95% CI, 1.351 to 20.396) with 3rd quartile of albumin levels and nodular and parenchimal IL size with 2nd (OR = 0.227; 95% CI, 0.053 to 0.981), 3rd (OR = 0.164; 95% CI, 0.038 to 0.711) and 4th (OR = 0.205; 95% CI, 0.048 to 0.870) quartiles albumin levels; e) smaller IL size with 3rd quartile triglycerides (TG) levels (OR = 9; 95% CI, 2.487 to 32.567) and an independent correlation with anterior location. Smaller IL size, anterior AIS turned out to be independently correlated with high serum albumin levels. Finally, high INR and PTT values were associated with worse NIHSS clinical outcomes in contrast to that observed with higher albumin level.
We provide evidence of routine biomarkers levels correlation with acute IL size, independently of age and sex. In addition, we highlight the importance of differentiation of biomarkers normal interval levels for further improvement not only of the clinical decision making but also in post-acute clinical outcome management.